Home > others & > Imiquimod

Imiquimod

咪喹莫特,R-837,S-26308,R 837,R837,S 26308,S26308,

Imiquimod是一种新型合成剂，具有免疫反应修饰活性。

目录号
EY1135
EY1135
EY1135
纯度
99.28%
99.28%
99.28%
规格
10 mg
50 mg
100 mg
原价
150
220
400
售价
150
220
400
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Imiquimod is a novel synthetic agent with immune response modifying activity.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Abdelouahid El‐Khattouti,et al. Imiquimod‐induced apoptosis of melanoma cells is mediated by ER stress‐dependent Noxa induction and enhanced by NF‐κB inhibition. J Cell Mol Med. 2016 Feb; 20(2): 266–286. Published online 2015 Nov 18. doi: 10.1111/jcmm.12718.
    [2] Kyung-Cheol Sohn,et al. Imiquimod Induces Apoptosis of Squamous Cell Carcinoma (SCC) Cells via Regulation of A20. PLoS One. 2014; 9(4): e95337. Published online 2014 Apr 17. doi: 10.1371/journal.pone.0095337.
    [3] Satheesh K. Sainathan,et al. The TLR7 ligand Imiquimod induces type I IFN and antimicrobial peptides to ameliorate DSS-induced acute colitis. Inflamm Bowel Dis. Author manuscript; available in PMC 2014 Jan 2. Published in final edited form as: Inflamm Bowel Dis. 2012 May; 18(5): 10.1002/ibd.21867. Published online 2011 Sep 26. doi: 10.1002/ibd.21867.

    分子式
    C14H16N4    		 分子量
    240.3    		 CAS号
    99011-02-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    4 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01264731 Melanoma Biological: MELITAC 12.1|Drug: Imiquimod University of Virginia Phase 1 2011-01-01 2016-12-15
    NCT00941252 Cervical Intraepithelial Neoplasia Drug: Topical imiquimod therapy Medical University of Vienna Phase 2|Phase 3 2009-07-01 2011-01-21
    NCT00189306 Superficial Basal Cell Carcinoma Drug: Imiquimod 5% cream Graceway Pharmaceuticals, LLC Phase 3 2001-03-01 2010-08-05
    NCT02130323 Cervical Intraepithelial Neoplasia Drug: Imiquimod|Procedure: Loop Electrosurgical Excision Procedure United States Naval Medical Center, San Diego Phase 2|Phase 3 2015-02-01 2016-09-27
    NCT01229319 Actinic Keratosis Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm Frankel, Amylynne, M.D.|Graceway Pharmaceuticals, LLC Phase 4 2010-10-01 2011-06-21
    NCT02329171 Cervical Intraepithelial Neoplasia Drug: Imiquimod|Procedure: LLETZ Maastricht University Medical Center|MEDA Pharma GmbH & Co. KG Phase 3 2014-12-01 2016-06-20
    NCT00585247 Port Wine Stain Drug: Imiquimod|Other: Placebo University of California, Irvine|Beckman Laser Institute University of California Irvine 2006-11-01 2015-08-05
    NCT00803907 Carcinoma, Basal Cell Drug: Imiquimod 5% cream University of Sao Paulo Phase 4 2008-12-01 2012-06-12
    NCT00899574 Breast Cancer|Breast Neoplasms Drug: Imiquimod New York University School of Medicine Phase 2 2009-05-01 2015-11-06
    NCT00116649 Keratosis Drug: imiquimod cream Graceway Pharmaceuticals, LLC Phase 4 2005-06-01 2010-07-14
    NCT02917746 Cervical Intraepithelial Neoplasia Drug: Imiquimod|Procedure: Large Loop Excision of the Transformation Zone Maastricht University Medical Center|Clinical Trial Center Maastricht 2016-11-01 2016-11-07
    NCT00865644 Neurofibromatosis Type 1|Cutaneous Neurofibromas Drug: Imiquimod 5% Cream Massachusetts General Hospital Phase 1 2009-03-01 2017-01-09
    NCT00849992 Actinic Cheilitis Drug: Imiquimod 5%|Procedure: Photodynamic therapy Norwegian University of Science and Technology|St. Olavs Hospital Phase 4 2009-03-01 2014-08-11
    NCT01203878 Actinic Keratosis Drug: Photodynamic therapy|Drug: Imiquimod Tennessee Clinical Research Center|Graceway Pharmaceuticals, LLC Phase 4 2010-09-01 2014-11-20
    NCT01283763 Cervical Intraepithelial Neoplasia Drug: Topical Imiquimod|Procedure: Conization Medical University of Vienna|Medical University of Graz|Medical University Innsbruck|Krankenhaus Barmherzige Schwestern Linz|Salzburger Landeskliniken Phase 3 2013-05-01 2016-10-30
    NCT02385188 Paget Disease, Extramammary Drug: Imiquimod|Drug: paracetamol|Drug: lidocaine in Vaseline ointment University Medical Center Nijmegen|Leiden University Medical Center|University Medical Center Groningen|Erasmus Medical Center|The Netherlands Cancer Institute|UMC Utrecht|Catharina Ziekenhuis Eindhoven Phase 3 2015-05-01 2016-10-07
    NCT00774787 Actinic Keratoses Drug: imiquimod 5% cream Rigel Dermatology Phase 4 2008-10-01 2016-10-03
    NCT01935310 Photoaging Drug: Imiquimod CES University 2010-07-01 2013-08-30
    NCT00638651 Healthy Device: 1064 nm Nd:YAG laser|Drug: Imiquimod, 5% cream University of Miami|Graceway Pharmaceuticals, LLC Phase 1 2008-02-01 2014-08-20
    NCT00601016 Hemangioma, Capillary Drug: Imiquimod 5% cream St. Justine's Hospital|Graceway Pharmaceuticals, LLC Phase 2 2005-03-01 2008-01-24

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：